ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

 ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance
                            of 20 Patents in 2012

PR Newswire

SAN DIEGO, Jan. 31, 2013

SAN DIEGO, Jan. 31, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative
medicine company focused on developing new approaches to treat major diseases
through the application of a stem cell-derived cell therapy, announced today
that the Company was granted 20 patents worldwide in 2012, eight U.S. and
twelve foreign. These patents bolster the Company's already strong
proprietary position for its ground-breaking diabetes product, VC-01, as well
as other applications of its broad technology platform.

(Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a)

VC-01 is a very promising, development-stage product that consists of
pancreatic precursor cells (called PEC-01) derived from a proprietary human
embryonic stem cell line and encapsulated in a proprietary, immune isolating
medical device (the ENCAPTRA^® device). When implanted under the skin in
suitable animal models, the cells further differentiate into insulin producing
and other endocrine cells that regulate blood glucose in a manner similar or
identical to a normal pancreas. If VC-01 performs in humans as it has in
animal studies, it could effectively cure type 1 diabetics and be an important
new therapy for insulin dependent type 2 diabetics.

ViaCyte's significant intellectual property portfolio now includes over 300
issued patents and pending applications related to the growth, directed
differentiation and use of human pluripotent stem cells such as human
embryonic stem cells and induced pluripotent stem cells. This portfolio
includes 51 issued U.S. and foreign patents specifically directed to the
Company's VC-01 product. In addition to the protection afforded by patents,
the Company also relies on significant proprietary know-how to develop its
product offerings.

Dr. Paul Laikind, ViaCyte's president and chief executive officer said, "Our
comprehensive and growing intellectual property portfolio helps to establish
us as a leading company in the cell therapy and regenerative medicine field.
Although the Company's resources are currently fully committed to the rapid
development of VC-01 as a potentially transformative treatment for patients
with insulin-dependent diabetes, our platform technology has many other
important applications."

In July and August of 2012, the Board of Patent Appeals and Interferences of
the U.S. Patent and Trademark Office (the "Board") also issued two decisions
favoring ViaCyte on motions filed in the patent interference proceedings
between ViaCyte and Geron Corporation (Menlo Park, California). The
interferences involved ViaCyte's U.S. Patent No. 7,510,876 ("876 Patent"),
which is directed to human definitive endoderm cell cultures in vitro. The
Board upheld the claims of ViaCyte's '876 Patent in its entirety over Geron's
applications. In September 2012, Geron appealed this decision in the United
States District Court for the Northern District of California. 

About ViaCyte
ViaCyte, a private company that has emerged as a leader in the field of
regenerative medicine, is currently focused on developing a novel cell therapy
for the treatment of diabetes. The Company's lead product is based on the
production of pancreatic progenitors derived from human pluripotent stem
cells. These cells are implanted in a durable and retrievable encapsulation
device. Once implanted and matured, these cells secrete insulin and other
regulatory factors in response to blood glucose levels. ViaCyte's goal for
this potentially transformative diabetes product is long term insulin
independence without immune suppression, and without risk of hypoglycemia and
other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations
in Athens, Georgia. The Company is funded in part by the California Institute
for Regenerative Medicine (CIRM) and JDRF.

SOURCE ViaCyte, Inc.

Contact: Liz Bui, Esq. Ph.D., +1-858-909-5309, Lbui@viacyte.com
 
Press spacebar to pause and continue. Press esc to stop.